Following Cathie Wood: Strategic bet on 'gene-editing rising star' NTLA, taking profits on aerospace asset RKLB while at a high

On Monday (April 27), the three major U.S. stock indices ended with a divergence in performance. The Dow closed lower, while the S&P 500 and Nasdaq edged up to new all-time highs. Tech giants performed strongly, $NVIDIA (NVDA.US)$and$Alphabet-C (GOOG.US)$all hitting record highs; among them, NVIDIA rose 4% to close at $216.61, with a market cap reaching $5.26 trillion. On the geopolitical front, U.S. President Trump announced the cancellation of a planned trip by U.S. representatives to Islamabad for talks with Iran, a move that significantly boosted international oil prices.

Under these market conditions, Cathie Wood continued to deepen her strategic position in gene editing and biotechnology on the buying side, while on the selling side, she took advantage of the market's peak to reduce holdings in aerospace and traditional satellite communication assets, which have recently experienced high volatility and face challenges to their competitive moats.

Buying direction: Sticking to the biotech sector, making a strong bet on gene repair potential

Buy $Intellia Therapeutics (NTLA.US)$Appointment263,800 shares。Intellia TherapeuticsIntellia Therapeutics has been a core holding of ARK in the gene editing field. Unlike traditional drug development, Intellia focuses on CRISPR-based in vivo gene editing technology, which is considered the 'ultimate weapon' for potentially curing genetic diseases in the future. Cathie Wood's recent increase in this position shows her further concentration on disruptive technology-based assets. Despite uncertainties in the commercialization process of gene editing, the ongoing progress in NTLA’s clinical data makes it an important part of ARK’s portfolio for seeking excess returns.

Selling direction: Taking profits at highs, divesting from 'technologically impaired' assets

As the market climbs to historic highs, ARK continues its strategy of weeding out weaker investments, pulling funds from sectors where moats are challenged or competition intensifies.

Reduce holdings $Rocket Lab (RKLB.US)$Appointment50,300 shares, exiting the intensified competition in the aerospace sectorAs a leader in the small rocket launch sector, Rocket Lab faces immense competitive pressure. With SpaceX increasing its launch frequency and further reducing costs, profit margins for small and medium-sized rocket companies continue to be squeezed. 'Woodpecker Sister' chose to reduce holdings amid a booming market, which is a typical case of taking profits at a high point, reallocating funds to technologically leading companies with higher certainty.

Reduce holdings $Iridium Communications (IRDM.US)$Appointment13,800 shares, continuing to divest 'old' assetsFollowing previous substantial sell-offs, ARK continues to divest from this traditional low-orbit satellite service provider. With SpaceX's Starlink aggressively advancing its 'direct-to-phone' business, IRDM’s traditional moat is facing collapse.

Futubull [Opportunities page] Now featuring the ability to track portfolios of renowned investors! Choose from multiple celebrity holdings, follow the investment strategies of top players with one click, accurately target high-quality stocks, and invest with greater confidence!

157K Views